Cannabidiol inhibitory effect on marble-burying behaviour: Involvement of CB1 receptors

Behavioural Pharmacology

Volumn 21, Issue 4, 2010, Pages 353-358

  Casarotto, Plinio C ^a   Gomes, Felipe V ^a   Resstel, Leonardo B M ^a   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cannabidiol; CB1 receptor; marble burying; mouse; obsessive compulsive disorder

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; DIAZEPAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; PLACEBO; SEROTONIN 1A RECEPTOR; HYPNOTIC SEDATIVE AGENT; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; COMPARATIVE STUDY; COMPULSION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL TEST; MALE; MARBLE BURYING TEST; MOUSE; NONHUMAN; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; MOTOR ACTIVITY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BEHAVIOR, ANIMAL; CANNABIDIOL; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPNOTICS AND SEDATIVES; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PAROXETINE; PIPERAZINES; PIPERIDINES; PYRAZOLES; PYRIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 77955168120     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833b33c5     Document Type: Article

References (36)

1. Aboujaoude E, Barry JJ, Gamel N (2009). Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psycho-pharmacol 29:51-55.
2. Abramowitz JS, Taylor S, McKay D (2009). Obsessive-compulsive disorder. Lancet 374:491-499.
3. Argyropoulos SV, Sandford JJ, Nutt DJ (2000). The psychobiology of anxiolytic drug. Part 2: pharmacological treatments of anxiety. Pharmacol Ther 88:213-227.
4. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845-852.
5. Bitencourt RM, Pamplona FA, Takahashi RN (2008). Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18:849-859.
6. Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL (1986). Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126:223-229.
7. Campos AC, Guimaraes FS (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaque-ductal gray of rats. Psychopharmacology (Berl) 199:223-230.
8. Carlsson ML (2000). On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand 102:401-413.
9. Carrier EJ, Auchampach JA, Hillard CJ (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103:7895-7900.
10. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735-1740.
11. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417-426.
12. Dolberg O, Lancu I, Zohar J (1996). Treatment duration of obsessive compulsive disorder. Eur Psychiatry 11:403-406.
13. Eddy KT, Dutra L, Bradley R, Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24:1011-1030.
14. Egashira N, Okuno R, Harada S, Matsushita M, Mishima K, Iwasaki K, et al. (2008a). Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 586:164-170.
15. Egashira N, Okuno R, Matsushita M, Abe M, Mishima K, Iwasaki K, et al. (2008b). Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. Eur J Pharmacol 592:103-108.
16. Grant P, Lougee L, Hirschtritt M, Swedo SE (2007). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 17:761-767.
17. Ichimaru Y, Egawa T, Sawa A (1995). 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 68:65-70.
18. Iijima M, Kurosu S, Chaki S (2010). Effects of agents targeting glutamatergic systems on marble-burying behavior. Neurosci Lett 471:63-65.
19. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515-527.
20. Korff S, Harvey BH (2006). Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am 29:371-390.
21. Moreira FA, Aguiar DC, Guimaraes FS (2006). Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466-1471.
22. Njung'e K, Handley SL (1991). Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38:63-67.
23. Onaivi ES, Green MR, Martin BR (1990). Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002-1009.
24. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL (1988). Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 145:1521-1525.
25. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884.
26. Pittenger C, Krystal JH, Coric V (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3:69-81.
27. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156:181-188.
28. Russo EB, Burnett A, Hall B, Parker KK (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037-1043.
29. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101.
30. Schindler F, Anghelescu I, Regen F, Jockers-Scherubl M (2008). Improvement in refractory obsessive compulsive disorder with dronabinol. Am J Psychiatry 165:536-537.
31. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R (2009). Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 204:361-373.
32. Umathe SN, Bhutada PS, Jain NS, Mundhada YR, Borkar SS, Dhumal B (2009a). Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice. Nitric Oxide 21:140-147.
33. Umathe SN, Manna SS, Utturwar KS, Jain NS (2009b). Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry 33:1191-1199.
34. Witkin JM (2008). Animal models of obsessive-compulsive disorder. Curr Protoc Neurosci 45:1-9.
35. Chapter 9. Unit 9 30. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR (2010). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159:122-128.
36. Zuardi AW, Guimaraes FS, Moreira AC (1993). Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 26:213-217.